ZBIO Investors Have Opportunity to Lead Zenas BioPharma, Inc. Securities Lawsuit Filed by The Rosen Law Firm

Provided By PR Newswire

Last update: May 31, 2025

NEW YORK, May 31, 2025 /PRNewswire/ --

Why: Rosen Law Firm, a global investor rights law firm, reminds purchasers of the securities of Zenas BioPharma, Inc. (NASDAQ: ZBIO) pursuant and/or traceable to the registration statement and prospectus (collectively, the "Registration Statement") issued in connection with Zenas BioPharma's September 2024 initial public offering ("IPO" or the "Offering"), of the important June 16, 2025 lead plaintiff deadline in the securities class action first filed by the Firm.